Authors
Latest:
Dr. Anne Marie McCarthy on Measuring Breast Density with Computer AlgorithmsAnne Marie McCarthy, MD, research fellow, Massachusetts General Hospital, discusses using computer algorithms to measure breast density.
Latest:
Dr. McTiernan on Biomarkers in Breast CancerAnne McTiernan, MD, PhD, research professor of epidemiology, University of Washington, member, Fred Hutchinson Cancer Research Center, discusses the biomarkers that are associated with poor prognosis in patients with breast cancer.
Latest:
Dr. Odisho on a Risk Prediction Model in Renal Cell CarcinomaAnobel Odisho, MD, urologic oncology fellow, University of Washington, discusses the use of a risk prediction model for patients with renal cell carcinoma.
Latest:
The Personal Touch: Patients Are More Than Their ChartsAnthony Accurso, MD, offers a patient more time managing their cancer and a better quality of life.
Latest:
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma: a randomized, phase 3 trialDr. El-Khoueiry evaluates the efficacy and safety of camrelizumab in combination with rivoceranib for the treatment of unresecetable hepatocellular carcinoma in the front-line setting.
Latest:
Testing Reveals Extent of Lynch SyndromeThe presence of Lynch syndrome correlates with microsatellite-instability status and DNA mismatch-repair deficiency across a variety of tumor types.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Dr. Costales on Study of Adjuvant Therapy in Uterine LeiomyosarcomaAnthony Costales, MD, gynecologic oncology fellow, Cleveland Clinic, discusses a study of adjuvant therapy for patients with uterine leiomyosarcoma.
Latest:
Dr. Elias on Androgen Receptor Inhibitors in HER2-Positive Breast CancerAnthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses using androgen receptor inhibitors as a potential treatment of patients with HER2-positive breast cancer.
Latest:
The Evolving Treatment Landscape of HCCClosing out their discussion on hepatocellular carcinoma, expert panelists consider future directions in care.
Latest:
Drs El-Khoueiry and Hughes-Halbert on the Importance of a Multidisciplinary Approach in Cancer CareAnthony B. El-Khoueiry, MD, and Chanita Hughes-Halbert, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Latest:
BCL-2 Inhibitors May Provide Avenue of Attack Against High-Risk NeuroblastomaInvestigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.
Latest:
CMS Unveils Proposed Radiation Oncology Model of CareUntil now, radiation oncology (RO) has remained largely untouched by the valuebased initiatives of the Centers for Medicare and Medicaid Services. The federal agency aims to change that with a proposed RO Model of care that would promote site-neutral payment and take away incentives for volume-based billing.
Latest:
Dr. Cmelak Discusses the Results of the ECOG1308 StudyAnthony J. Cmelak, MD, professor, Radiation Oncology, Vanderbilt-Ingram Cancer Center, discusses the results of ECOG1308, a study that evaluated reduced-dose IMRT in HPV-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response to induction chemotherapy.
Latest:
Dr. Olszanski Discusses Advances in Stage III MelanomaAnthony J. Olszanski, MD, RPh, vice chair, Department of Hematology/Oncology, director, Early Drug Development Phase I Program, Fox Chase Cancer Center, discusses treatment advances in stage III melanoma.
Latest:
Dr. Magliocco on Analyzing the Genome of Melanoma TumorsAnthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the difficulties of analyzing the genome of melanoma tumors.
Latest:
Dr. Mato on the Potential Use of Noncovalent BTK Inhibitors in CLLAnthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.
Latest:
The Future of the Treatment Landscape in MZL and FLKey opinion leaders in hematology-oncology consider the future treatment landscape for marginal zone and follicular lymphomas and reflect on the role of chemotherapy and targeted agents as induction or maintenance.
Latest:
Noncovalent BTK Inhibitors in CLLRecommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.
Latest:
Closing Remarks on Upcoming Data and Future Perspectives in MCL and CLLLooking to the future, a panel of experts offers closing remarks on research in CLL and MCL including hopes for further data on bispecific antibodies, BTK degraders, CAR T-cell therapy, and pirtobrutinib.
